UNSPSC 51401515: Clobazam

This classification denotes an anxiolytic with the molecular formula C16H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2MRO291B4U, chemically known as 7-chloro-1-methyl-5-phenyl-1h-1,5-benzodiazepine-2,4(3h,5h)-dione but generally known as clobazam, which bears US NIH Compound Identifier 2789. European Medicines Agency schedules Clobazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06673MIG.

UNSPSC 51401515 Clobazam is a Commodity code that in recent state and local activity does not align meaningfully with actual procurement activity. The code nominally identifies a specific anticonvulsant pharmaceutical, yet the recent opportunities tagged to this code—naloxone procurement, direct-to-manufacturer prescription program design, and multi-source generic pharmaceutical supply contracts—address different therapeutic categories and procurement models entirely. State and local governments buying under this code designation are instead procuring naloxone for opioid-overdose response, exploring direct manufacturer relationships to manage pharmacy benefit costs, and establishing cooperative purchasing vehicles for generic and OTC pharmaceutical distribution through authorized wholesalers. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, with participation from Oregon and other member jurisdictions).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2026; the Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription contracting; and the Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026. The MMCAP vehicle carries a two-year initial term with optional extensions and reserves the right to make sole, dual, or multi-awards; vendors must maintain specified insurance coverage, comply with cGMP and DSCSA requirements, and absorb a 3 percent administrative fee on all contract purchases. The mismatch between the code's nominal scope and the actual procurement activity suggests this code is not a reliable entry point for pharmaceutical vendors seeking state and local opportunities in these categories.